November 16, 2010 (FinancialWire) (Go to http://www.financialwire.net/?s=ftrdnwswnd for all of today’s featured news.) — Clinical Data, Inc. (CLDA) today announced that the company has filed a shelf registration statement with the Securities and Exchange Commission to permit the firm to offer and sell up to $200 million of its common stock, preferred stock, debt securities or any combination of these.

The firm said it does not have any current plans to sell shares under the registration statement, but that proceeds from any offering could be used for general corporate purposes, including financing the launch and other commercial activities for its vilazodone drug if approved by the U.S. Food and Drug Administration, continued clinical development of Stedivaze and advancement of the company’s follow-on therapeutics pipeline.

Massachusetts-based Clinical Data is developing therapeutics for central nervous system disorders and cardiovascular diseases, to be followed by drug candidates in major therapeutic areas including oncology and inflammatory diseases.

=========

Resource note: Marshal Shichtman & Associates, P.C., is collaboration with Investrend Communications, provides a unique independent equity research product, which includes a specialized component particularly focused on assistance in best practices, filings, reporting, good governance and litigation avoidance. For a preferred introduction to Mr. Shichtman and/or more information about Investrend’s specialized program, write to resources@investrend.com with “Shichtman Introduction” in the subject line.

=========

Equity research on any public company is available through the Shareholders Research Alliance (go to http://www.investrend.com/synd0004 for more information).  Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://investrend.stocksmart.com/ss/html/hpcompany.html).  Current valuation analysis research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://www.valuengine.com/rep/searchsrep?pid=42&srchfor=).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public other companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation from subject entities, companies, equities, or representatives thereof, for its news, opinions or distributions. Further disclosure is posted at the FinancialWire(tm) website (at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Copyright © MMX, FinancialWire(tm); All rights reserved.

[hlmsmlh] [rgltryrtl] [cmplncz] [gvrncnr] [fnncngj] [hlthcrdp] [biomedphrm] [ftrdnwswnd] [bsdarrgnmnt]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.